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Abstract
The latest statistics indicate that the number of people infected with human immunodeficiency virus type 1 (HIV-1) worldwide 
is 40.3 million, 25.8 million of whom live in sub-Saharan Africa. In 2004, 29.5% of South African women attending antena-
tal clinics were infected. The virus infects people of all ages and social classes. A diagnosis of HIV has serious physical, 
emotional and social implications for the patient. HIV-infected patients are susceptible to numerous opportunistic and other 
infections, as well as to non-infectious diseases such as tumours. They eventually require lifelong treatment with potentially 
toxic medication. It is therefore essential that a timeous and correct diagnosis be made. 
An understanding of the tests available for the diagnosis and monitoring of HIV is essential for all clinicians working in South 
Africa. Tests available for the diagnosis of HIV in patients older than 18 months include HIV-specific antibody assays, fourth-
generation combination antibody-antigen assays and Western Blot. The diagnosis of HIV infection in infants younger than 18 
months requires detection of the virus itself by means of p24 antigen detection or HIV DNA PCR. The CD4+ T lymphocyte 
count and HIV viral load are used for monitoring disease progression and response to therapy.
Introduction
The latest statistics indicate that the 
number of people infected with hu-
man immunodeficiency virus type 1 
(HIV-1) worldwide is 40.3 million 1, of 
whom 25.8 million live in sub-Saharan 
Africa. In 2004, 29.5% of South African 
women attending antenatal clinics were 
infected 2.  The virus infects people of 
all ages and social classes. A diagnosis 
of HIV has serious physical, emotional 
and social implications for the patient. 
HIV infected patients are susceptible 
to numerous opportunistic and other 
infections, as well as non-infectious 
diseases such as tumours. They even-
tually require lifelong treatment with po-
tentially toxic medication. It is therefore 
essential that a timeous and correct 
diagnosis be made. 
Back to Basics
HIV is classified in the genus Lentivirus 
of the family Retroviridae. There are two 
species of HIV within the genus: HIV-1 
and HIV-2. HIV-1 is responsible for the 
global pandemic with HIV-2 accounting 
for infections predominantly confined 
to West Africa. HIV-1 is further divided 
into three groups namely M, N and O. M 
is responsible for the majority of infec-
tions. There are nine subtypes within 







Figure 1: The structure of HIV 
HIV has a genome composed of two 
single strands of RNA. Closely associated 
with the genome is the enzyme reverse 
transcriptase. The genome is surrounded 
by a capsid composed of the protein p24. 
The virus is surrounded by a lipoprotein 
membrane containing the glycoproteins 
gp120 and gp41.
inter-subtype circulating recombinant 
forms (CRFs) 3, 4. 
HIV contains a genome made up of 
two single strands of RNA. Surround-
ing the genome is a capsid composed 
of the p24 protein (antigen). The viral 
particle is surrounded by a lipoprotein 
membrane containing glycoproteins, 
namely gp120 and gp41 (Figure 1). 
Upon entry into a CD4+ cell, the viral 
enzyme reverse transcriptase converts 
the viral RNA into DNA. The viral DNA 
is transported to the nucleus of the cell 
where it is integrated into the host DNA. 
Once integrated the viral DNA is referred 
to as proviral DNA. HIV thus essentially 
becomes an acquired genetic disease. 
Proviral DNA is transcribed to RNA that 
is then translated into viral proteins. 
These viral proteins are processed to 
form new viral particles that bud from 
the cell membrane and are able to infect 
new CD4+ cells (Figure 2).
After infection with HIV, the virus 
replicates to a high viral load (up to mil-
lions of copies) prior to the host mount-
ing an immune response. Although the 
immune response is unable to eradicate 
the infection, it is able to bring the viral 
replication under control. This causes 
the viraemia to decrease until it reaches 
a viral setpoint i.e. a stable viral load 
that is maintained until the immune 
system becomes depleted. The viral 
setpoint is a strong predictor of the rate 
of disease progression, i.e. the higher 
the setpoint, the quicker the disease 
will progress. Once the immune system 
becomes exhausted by the ongoing 
infection, the viral load will once again 
increase as the CD4+ T lymphocyte 
count decreases 5 (Figure 3).
The first detectable marker of infec-
tion is HIV RNA. The earliest it can be 
detected is 11 days post-infection. HIV 
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New viral particles bud
from the cell
Figure 2: The life cycle of HIV. DNA and the p24 antigen are detectable 
from approximately 16 days post-infec-
tion. HIV-specific antibodies become 
detectable at the earliest at 24 days, 
but a small percentage of individuals 
may take as long as two months to pro-
duce detectable antibodies 6. The p24 
antigen often becomes undetectable 
once the viral setpoint is reached and 
only becomes detectable again towards 
the terminal stages of the disease when 
the immune system is no longer able to 
control viral replication.
Diagnosis of HIV in patients older 
than 18 months of age
When testing for HIV one needs to 
consider:
•  the sensitivity and specificity of the 
test
•  the ability of the test to detect all 
stages of infection
•  the ability of the test to detect all 
types and subtypes of the virus
• the cost of the test.
The basis of HIV testing is the detection 
of HIV-specific antibodies. These are 
present in virtually 100% of patients 
with HIV infection and their presence 
indicates infection. An ELISA (enzyme 
linked immunosorbent assay) is the 
method used to detect antibodies or 
antigen. Previous assays (1st – 3rd gen-
eration assays) detected HIV-specific 
antibodies alone. The 4th generation 
combination assays that are now avail-
able detect HIV-specific antibodies and 
the p24 antigen simultaneously. This 
has the advantage of shortening the 
window period to a minimum of 18 days 
as well as increasing the detection of 
HIV in late disease when HIV-specific 
antibody levels may be low. The assays 
are also designed in such a way as to 
detect HIV-1 and HIV-2, as well as the 
majority of subtypes and CRFs. The 
present day assays are almost 100% 
sensitive and approximately 99.7% 
specific for HIV infection 7. It is essential 
to do a confirmatory test if the screen-
ing test is positive/reactive, in order to 
exclude false positives. In addition, a 
second specimen should be sent for 
repeat testing to avoid any errors, such 
as mislabelled specimens.
A p24 antigen ELISA on its own 
should not be used to diagnosis HIV 
outside the seroconversion phase as it 
is only 79% sensitive and, as mentioned 
earlier, may be negative during a large 
portion of the disease process 8. Quali-
tative HIV RNA and DNA PCRs are 
available, but are expensive. Their use 
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Figure 3: Immunological markers for HIV
Viral RNA is detectable in the blood from approximately 11 days post-infection. There is a 
rapid rise in viral RNA levels (viral load) until the immune system responds, after which the 
RNA levels decrease to a viral set point that is maintained for a prolonged period. HIV DNA 
and p24 become detectable in the blood from approximately 16 days post-infection. p24 le-
vels then become undetectable until the end stage of disease, at which time p24 levels rise. 
HIV antibodies are detectable from approximately 24 days post-infection.
HIV enters a CD4+ cell and its genome is released into the cytoplasm. Reverse transcriptase 
converts the viral RNA into DNA. The DNA is transferred to the nucleus of the cell where it 
becomes integrated into the host cell DNA. The integrated/proviral DNA is transcribed to RNA 
and translated into viral proteins. Viral proteins assemble to form new viral particles that bud 
from the cell surface.
is not advised for routine testing due to 
the availability of reliable, cheaper op-
tions.
Western Blot was previously used as 
a confirmatory test. Antibodies directed 
against HIV proteins bind to relevant 
areas on a strip and are detected by the 
addition of an enzyme-labelled second-
ary enzyme and substrate. Most labora-
tories no longer use Western Blot, as it 
is expensive and labour intensive, and 
3rd and 4th generation ELISA assays 
are more reliable than those previously 
available. The Western Blot is however 
a useful tool for differentiating between 
infections with HIV-1 and HIV-2.
Diagnosis of HIV in patients younger 
than 18 months of age
The risk of vertical transmission of HIV 
from an infected mother to her infant 
is 15-30%. With intervention, i.e. cae-
sarean section, formula feeding and 
antiretroviral prophylaxis or HAART 
(highly active antiretroviral therapy), 
the risk decreases to less than 2% 9. 
Maternal HIV-specific antibodies may 
be detectable in the infant’s blood for 
up to 18 months of age. It is therefore 
essential to distinguish between pas-
sively acquired antibodies and active 
HIV infection.
If a 4th generation ELISA assay gives 
a positive/reactive result, it does not 
distinguish between antibodies and 
antigen. If a 4th generation assay or any 
other antibody assay gives a positive/
reactive result, a separate p24 antigen 
assay should be performed. If the p24 
antigen is positive, the infant is infected 
with HIV. If the p24 antigen is negative, 
Table I: Tests available for the diagnosis of HIV
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it does not preclude the possibility of 
infection as mentioned previously. 
HIV-1 DNA PCR is the mainstay of 
HIV-1 diagnosis in infants. The assay 
detects HIV-1 viral DNA in leukocytes. 
The South African Department of 
Health recommends testing the infant 
at 6 weeks and if negative, again at 4 
months 10. The second test at 4 months 
of age is necessary to detect infected 
infants who may have had undetectable 
levels of HIV-1 DNA at initial testing 
11. If there is ongoing exposure e.g. 
breastfeeding, the test will need to be 
repeated six weeks after the exposure 
has ceased. A positive result should be 
confirmed on a second specimen.
Rapid HIV testing
A number of rapid tests are available 
for the detection of HIV-specific anti-
bodies. These tests provide a result 
within 15-30 minutes. They are of use 
when a result is required quickly in an 
emergency situation or at clinics where 
results are provided immediately to pa-
tients who may not return. Rapid tests 
are not as sensitive or specific as 4th 
generation assays. Some rapid tests 
detect HIV-1-specific antibodies only, 
while others detect HIV-1- and HIV-2-
specific antibodies. All results obtained 
by rapid testing should be confirmed as 
both false positive and false negative 
results can occur 12.  
MONITORING DISEASE PROGRES-
SION AND RESPONSE TO THERAPY
Monitoring of HIV-1 infection should 
not rely on any single marker. The 
patient’s clinical condition needs to 
be considered in addition to the HIV-1 
viral load and the CD4+ T lymphocyte 
count.
HIV-1 Viral Load
Quantitative HIV-1 RNA testing (HIV-
1 viral load) detects and quantifies 
the HIV-1 RNA in plasma. The viral 
load is given as a value representing 
RNA copies per millilitre, as well as a 
log value, e.g. 100 = 2 log, 1000 = 3 
log, 10000 = 4 log etc. The log value 
provides an easier number to work with 
and better indicates significant changes 
in viral load.
This test serves a number of purposes:
•  It determines the viral setpoint and 
acts as a long-term predictor of 
prognosis.
•  It acts as a guide for deciding when 
to initiate HAART. Certain guidelines 
recommend starting treatment if the 
viral load is greater than 100 000 
copies/ml, unless the patient has 
been recently infected and has not 
yet reached a viral setpoint.
•  It is a measure of viral response to 
therapy. An acceptable response to 
therapy is considered to be:
  o  a viral load reduction of more than 
1 log from the baseline value after 
6-8 weeks of therapy.
 o  a viral load of 5000 copies or less 
after 12 weeks of therapy.
 o  a viral load below detection limit 
of the assay after 12-24 weeks of 
therapy.
•  It is an indicator of the development 
of viral resistance to therapy:
 o  Primary failure of therapy is 
indicated by a viral load that does 
Test Indication
Rapid HIV test Immediate result required e.g. emergency situation or patient unlikely to return for result
4th generation HIV ELISA Diagnosis of HIV infection in patients >18 months of age.Screening for exposure in infants < 18 months of age.
HIV-specific antibodies 
(1st – 3rd generation ELISAs)
Diagnosis of HIV infection in patients >18 months of age.
Screening for exposure in infants < 18 months of age.
p24 antigen Diagnosis of acute seroconversion.Diagnosis of HIV infection in patients < 18 months of age
HIV-1 DNA PCR Diagnosis of HIV-1 infection in patients < 18 months of ageTable II: Tests available for monitoring HIV infection
Test Indication
CD4+ count
Monitoring of disease progression
Indicator of when to initiate HAART
Monitoring immunological response to therapy
HIV viral load Prognostic indicatorMonitoring virological response to therapy
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not decrease as expected after 
initiation of HAART.
 o  Secondary failure of therapy 
refers to an increase in the viral 
load of 1 log or greater on two 
separate specimens at least 
two weeks apart after an initial 
adequate response to HAART 13, 
14, 15.
It must be noted that the HIV-1 viral load 
should not be used for the diagnosis of 
HIV-1 infection. This is because low 
false positive results (usually less 
than 2000 copies/ml) can occur with 
quantitative HIV-1 RNA testing. Such 
results can lead to confusion and 
misdiagnosis.
A viral load result below the assays 
lower detection limit (LDL) may be due 
to:
• effective HAART. 
• lack of HIV-1 infection. Check 
the patient’s HIV status.
• failure of the assay to detect 
the patient’s variant of HIV. 
Commercially available HIV-
1 viral load assays detect 
only HIV-1 and not HIV-2. 
Most assays do not detect all 
variants of HIV-1.
The HIV-1 viral load must always be 
correlated with the patient’s clinical 
picture and CD4+ T lymphocyte count.
CD4+ T lymphocyte count 
For completeness, a mention must be 
made of the CD4+ T lymphocyte count. 
The CD4+ T lymphocyte count declines 
with acute infection. Once the viral load 
has reached its setpoint, the CD4+ T 
lymphocyte level increases, but rarely 
returns to pre-infection levels. As the 
immune system becomes exhausted, 
the CD4+ T lymphocyte count begins 
to decrease. 
There are a number of different 
guidelines available recommending 
when to start HAART. The World Health 
Organisation recommends initiating 
HAART when the CD4+ T lymphocyte 
count is less than 200 cells/ml or higher 
if the patient has an AIDS-defining 
illness. The South African National 
Antiretroviral Treatment Guidelines 
agree with the WHO. The Southern 
African HIV Clinicians Society 
recommends initiating HAART as 
above, but also advises initiation if the 
CD4+ T lymphocyte count is 200-350 
and has been shown to be decreasing 
rapidly. North American and European 
Guidelines offer HAART for CD4+ T 
lymphocyte counts less than 350 cells/
ml 16.
The CD4+ T lymphocyte count 
should be tested after diagnosis of HIV 
infection. If HAART is not yet indicated, 
the CD4+ T lymphocyte count should 
be repeated every 3-6 months. Once 
on treatment, the CD4+ T lymphocyte 
count should be monitored every 6 
months. 
A patient requiring HAART should be 
managed by a medical practitioner with 
experience in the care of patients with 
HIV.
 P  This article has been peer reviewed
References
1.  UNAIDS/WHO AIDS Epidemic Update: 
Global Summary of the AIDS Epidemic 
Dec 2005. http://www.unaids.org/epi/
2005/doc/report; accessed 6 April 
2006.
2.  UNAIDS/WHO AIDS Epidemic Update: 
Sub-Saharan Africa Dec 2005. http:
//www.unaids.org/epi/2005/doc/report; 
accessed 6 April 2006.
3.  Geretti AM. HIV-1 subtypes: epidemiol-
ogy and significance for HIV manage-
ment.  Curr Opin Infect Dis 2006, 19:
1–7.
4.  Linal ML, Fan H, Hahn B, Lwer R, Neil 
J, Quackenbush S et al. The reverse 
transcribing DNA and RNA viruses. 
In: Fauquet CM, Mayo MA, Maniloff J, 
Desselberger U, Ball LA, editors. Virus 
Taxonomy. 8th Report. California: Else-
vier Academic Press; 2005. p421-436.
5.   Wei X, Ghosh SK, Taylor ME. Viral 
dynamics in Human Immunodeficiency 
Virus type 1 infection. Nature 1993, 373:
117-122.
6.  Busch MP, Satten GA. Time course 
of viraemia and antibody seroconver-
sion following human immunodefi-
ciency virus exposure. Am J Med 1997, 
102(suppl.5B); 117-24.
7.  Duong Ly T, Laerche S, Brennan C, 
Vallari A, Ebel A, Hunt J et al. Evalu-
ation of the sensitivity and specificity 
of six HIV combined p24 antigen and 
antibody assays. J Viro Met 2004, 122:
185-194.
8.  Hecht FM, Busch FM, Rawal B, Webb 
M, Rosenberg E, Swanson M et al. Use 
of laboratory tests and clinical symp-
toms for identification of primary HIV 
infection. AIDS 2002, 16: 1119-1129.
9.  England K, Thorne C, Newell M. Verti-
cally acquired paediatric coinfection 
with HIV and hepatitis C virus. Lancet 
Infect Dis 2006, 6: 83-90.
10.  South African Department of Health. 
Guidelines for the Management of 
HIV-Infected Children 2005. http://
www.doh.gov.za/docs/policy; accessed 
10 April 2006.
11.  Newell ML, Loveday C, Dunn D, Kaye 
S, Tedder R, Peckham C et al. Use of 
Polymerase Chain Reaction and quan-
titative antibody tests in children born 
to human immunodeficiency-1 infected 
mothers. J Med Virol 1995 Dec, 47; 4:
330-335.
12.  Giles RE, Perry KR, Parry JV. Simple/
rapid test devices for anti-HIV screen-
ing: Do they come up to the mark? J 
Med Virol 1999 Sept, 59; 1:104-109.
13.  Powderly WG, Saag MS, Chapman S, 
Yu G, Quant B, Clendeninn NJ. Predic-
tors of optimal virological response to 
potent antiretroviral therapy. AIDS 1999 
Oct 1, 13; 14:1873-80.
14.  Spencer D. The Clinical Practice of 
HIV Medicine. Goldstream Publishers. 
Johannesburg 2005, p 4-30.
15.  National Department of Health. Anti-
retroviral Therapy in Adults. National 
Antiretroviral Therapy Guidelines 1st 
ed. 2004. http://www.doh.gov.za/docs/
factsheets; accessed April 6, 2006.
16.  Adult Guidelines Committee. Southern 
African HIV Clinicians Society. Antiret-
roviral therapy in adults. South Af J HIV 
Med 2002, 8:22-29.
Review
SA Fam Pract 2006:48(8) 46  c
